B. Metzler Seel. Sohn & Co. Ag Bridge Bio Pharma, Inc. Transaction History
B. Metzler Seel. Sohn & Co. Ag
- $10 Billion
- Q3 2024
A detailed history of B. Metzler Seel. Sohn & Co. Ag transactions in Bridge Bio Pharma, Inc. stock. As of the latest transaction made, B. Metzler Seel. Sohn & Co. Ag holds 36,603 shares of BBIO stock, worth $1.03 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
36,603
Previous 29,089
25.83%
Holding current value
$1.03 Million
Previous $736,000
26.49%
% of portfolio
0.01%
Previous 0.01%
Shares
8 transactions
Others Institutions Holding BBIO
# of Institutions
290Shares Held
170MCall Options Held
10.4MPut Options Held
2.37M-
Kohlberg Kravis Roberts & Co. L.P. New York, NY25.3MShares$714 Million35.94% of portfolio
-
Viking Global Investors LP25.1MShares$710 Million2.47% of portfolio
-
Vanguard Group Inc Valley Forge, PA14.2MShares$401 Million0.01% of portfolio
-
Black Rock Inc. New York, NY12.4MShares$352 Million0.01% of portfolio
-
Aisling Capital Management LP New York, NY6.07MShares$171 Million63.58% of portfolio
About BridgeBio Pharma, Inc.
- Ticker BBIO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 148,246,000
- Market Cap $4.19B
- Description
- BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabili...